Structure Therapeutics ($GPCR) Insider Trading & Smart Money Activity
Structure Therapeutics Inc. ($GPCR) has 8 insider trades, 1 13F position change and 2 analyst ratings on file. Insiders filed 8 Form 4 transactions in the last 12 months, none of them open-market purchases or sales.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- $0
- Congress trades (12 mo)
- 0
- 13F moves on file
- 1
- Analyst ratings on file
- 2
GPCR insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 1 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All GPCR insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Xichen LinCHIEF SCIENTIFIC OFFICER | Sell (Option exercise) | 23.63K sh | +10.8% | +0.9% | — | |||||
| Insider | Xichen LinCHIEF SCIENTIFIC OFFICER | Buy (Option exercise) | 23.63K sh | $8.04K | +10.8% | +0.9% | Read | ||||
| Insider | Daniel Welch | Buy (Grant or award) | 39.45K sh | +7.0% | +7.7% | — | |||||
| Insider | Joanne Waldstreicher | Buy (Grant or award) | 39.45K sh | +7.0% | +7.7% | — | |||||
| Insider | Sharon Tetlow | Buy (Grant or award) | 39.45K sh | +7.0% | +7.7% | — | |||||
| Insider | Angus Russell | Buy (Grant or award) | 39.45K sh | +7.0% | +7.7% | — | |||||
| Insider | Ted Love | Buy (Grant or award) | 39.45K sh | +7.0% | +7.7% | — | |||||
| Insider | Eric Dobmeier | Buy (Grant or award) | 39.45K sh | +7.0% | +7.7% | — | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $70 | +2.8% | +19.3% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $70 | +2.8% | +19.3% | Read | |||||
| 13F | Pentwater Capital Management | New | +245K sh | $13.15M | +1.3% | +11.3% | — |
1W / 1M / 6M = how GPCR moved from the trade or filing date.
Insider trading in GPCR: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 2 | — | Jun 25, 2026 | |
| Daniel Welch | 1 | — | Jun 17, 2026 | ||
| Joanne Waldstreicher | 1 | — | Jun 17, 2026 | ||
| Sharon Tetlow | 1 | — | Jun 17, 2026 | ||
| Angus Russell | 1 | — | Jun 17, 2026 | ||
| Ted Love | 1 | — | Jun 17, 2026 | ||
| Eric Dobmeier | 1 | — | Jun 17, 2026 |
Institutions moving GPCR (13F)
Analyst ratings on GPCR
Frequently asked questions
What is the latest insider trade in GPCR?
Xichen Lin, CHIEF SCIENTIFIC OFFICER filed a sell (option exercise) of 23.63K sh on Jun 25, 2026.
Which institutions changed their GPCR positions?
Recent 13F filers moving the stock include Pentwater Capital Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.